Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
What the film says
When a high-grade glioma returns after standard treatment, there is no agreed next step. And the tumor walls itself off, releasing a signal, TGF-beta, that tells immune cells to stand down.
The idea: go after the protein that holds that signal on the cell surface.
It is called GARP; tumors with a lot of it do worse. A patient's own T cells are fitted with a receptor for it. At surgery, a small reservoir is placed under the scalp, and over five weeks the cells go straight into the cavity the tumor left.
In mice, the cells worked against several glioblastoma models without serious harm. This trial, at Ohio State with Brad Elder, asks first whether it is safe. Public record; not medical advice.
Sources behind this film
No standard next step at recurrence; Glioblastomas with a lot of GARP do worse; Own T cells, CAR for GARP, reservoir placed at surgery, five weekly intracavitary infusions; In mice, worked against several models without serious harm (+1 more lines)
Wu BX. Neuro Oncol, 2025
TGF-beta tells nearby immune cells to stand down; GARP holds the latent signal on the cell surface
The drug
PRIMARY OBJECTIVE: I. To assess the safety and feasibility of a CAR T targeting GARP for glioma by defining rate, frequency, and severity of dose limiting toxicities (DLT) following intracavity administration to patients with recurrent glioma, to determine recommended phase II dose (RP2D). SECONDARY OBJECTIVES: I. To describe the adverse event profile of anti-GARP CAR T cell therapy. II.
To describe the cytokine levels and immunophenotype in cerebrospinal fluid (CSF) during and following anti-GARP CAR T cell therapy. III. To describe the duration of anti-GARP CAR T cell persistence and phenotype in CSF. IV. To describe anti-tumor activity of anti-GARP CAR T cell therapy based on objective response rate (ORR), as measured by established radiological criteria. V.
Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.
The study
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells.
T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.